Back to top
more

Emergent Biosolutions (EBS)

(Real Time Quote from BATS)

$9.33 USD

9.33
786,125

+0.37 (4.13%)

Updated Nov 6, 2024 03:08 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Balance Sheet

Research for EBS

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Emergent Biosolutions Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 112 643 576 622 168
Receivables 191 158 275 231 275
Notes Receivable 0 0 0 0 0
Inventories 329 352 351 307 223
Other Current Assets 48 58 70 37 20
Total Current Assets 680 1,211 1,272 1,196 686
Net Property & Equipment 383 818 800 644 542
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 13
Intangibles 567 947 830 930 980
Deposits & Other Assets 194 191 57 113 106
Total Assets 1,823 3,167 2,959 2,883 2,327
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 112 104 129 136 95
Current Portion Long-Term Debt 414 957 0 34 13
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 93 123 140 132 102
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 33 46 105 83 7
Total Current Liabilities 651 1,230 374 385 216
Mortgages 0 0 0 0 0
Deferred Taxes/Income 47 72 95 109 150
Convertible Debt 0 0 0 0 0
Long-Term Debt 447 449 809 841 798
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 29 33 62 102 75
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 1,174 1,784 1,340 1,436 1,239
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 904 874 829 785 716
Retained Earnings -22 734 958 727 422
Other Equity -6 3 -16 -25 -10
Treasury Stock 228 228 152 40 40
Total Shareholder's Equity 649 1,383 1,619 1,447 1,089
Total Liabilities & Shareholder's Equity 1,823 3,167 2,959 2,883 2,327
Total Common Equity 649 1,383 1,619 1,447 1,089
Shares Outstanding 51.80 49.80 53.80 53.00 51.60
Book Value Per Share 12.53 27.77 30.09 27.30 21.09

Fiscal Year End for Emergent Biosolutions Inc falls in the month of December.

All items in Millions except Per Share data.

9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023
Assets          
Cash & Equivalents -99,999 71 79 112 88
Receivables NA 196 234 191 217
Notes Receivable NA 0 0 0 0
Inventories NA 318 333 329 354
Other Current Assets NA 70 37 48 62
Total Current Assets NA 655 682 680 721
Net Property & Equipment NA 306 379 383 395
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 534 550 567 583
Deposits & Other Assets NA 19 191 194 194
Total Assets NA 1,514 1,804 1,823 1,893
Liabilities & Shareholders Equity 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 96 100 112 113
Current Portion Long-Term Debt NA 415 459 414 414
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 84 56 93 100
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 25 15 33 38
Total Current Liabilities NA 620 630 651 664
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 35 35 47 52
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 447 447 447 448
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 28 29 31
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 1,127 1,140 1,174 1,196
Shareholders Equity 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 915 910 904 900
Retained Earnings NA -296 -13 -22 28
Other Equity NA -6 -6 -6 -3
Treasury Stock NA 228 228 228 228
Total Shareholder's Equity NA 386 664 649 697
Total Liabilities & Shareholder's Equity NA 1,514 1,804 1,823 1,893
Total Common Equity 0 386 664 649 697
Shares Outstanding 52.90 52.90 52.40 51.80 51.80
Book Value Per Share 0.00 7.30 12.67 12.53 13.46